30 Days in Home Use and Home Use Patterns Over 6 Months
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01882699|
Recruitment Status : Completed
First Posted : June 20, 2013
Last Update Posted : May 22, 2015
This study will build upon a previously approved protocol entitled "A multi-center prospective, blinded, randomized crossover study to compare the Cerêve Sleep System at two different temperatures in primary insomnia patients" (CIP-003; CER1-01-090). In that study, 150 insomnia patients were targeted to be randomized to complete in lab assessments of sleep using the Cerêve Sleep System. In this follow-on study, 36 patients who completed the in lab study will be enrolled to complete 2 phases of in home use of the device. In the first phase, the durability study, 30 patients are targeted to complete additional in lab assessments following 30 days of in home use of the device. In the second phase, the home use pattern study, 24 patients are targeted to complete an additional 5 months of in home use in which their use patterns will be monitored.
EEG sleep latency and sleep efficiency following 30 days in home use of the device at 14-16°C will be similar to those measures after the initial acute, 2-night use in the parent study in the 14-16°C condition. The device will demonstrate a benign safety profile over 6 months in home use.
|Condition or disease||Intervention/treatment||Phase|
|Primary Insomnia||Device: Cereve Sleep System||Not Applicable|
Study Design Objectives of the Clinical Investigation
- Assess polysomnographically measured sleep latency and sleep efficiency following 30 days in home use of the device and compare these measures with those following initial in lab use in the CIP-003 protocol.
- Determine the long-term use patterns of the Cerêve Sleep System in the environment of intended use.
Study Design Overview A multi-center, prospective, non-randomized, two phase study to determine durability of effects following 30 days of in home use (phase I) and home use patterns over an additional 5 months in home use of the Cerêve Sleep System (phase II).
A total of 30 evaluable subjects will be targeted to complete phase I and a total of 24 evaluable subjects will be targeted to complete phase II. It is anticipated that 36 subjects will be enrolled into the CIP-004 protocol to obtain the numbers of evaluable subjects described.
During in home use in both the durability phase and the home use patterns phase, the subject will be asked to use the device for a minimum of three nights each week for at least 4 hours on each of these nights up to seven nights each week. Subjects will complete a weekly home use log throughout both phases of the study.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multi-center, Prospective, Non-randomized Study to Determine Durability of Effectiveness of the Cerêve Sleep System Following 30 Days in Home Use and Home Use Patterns Over 6 Months|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||December 2013|
|Actual Study Completion Date :||December 2013|
Experimental: Cereve sleep system
Cereve sleep system
Device: Cereve Sleep System
- sleep latency [ Time Frame: 30 days ]latency from time in bed to persistent sleep
- sleep efficiency [ Time Frame: 1 month ]time asleep/time in bed
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01882699
|United States, Florida|
|St Petersburgh, Florida, United States, 33707|
|United States, Georgia|
|Atlanta, Georgia, United States, 30342|
|Atlanta, Georgia, United States, 30342|
|United States, Kentucky|
|Crestview HIlls, Kentucky, United States, 41047|
|Principal Investigator:||Alan Lankford, PhD||Sleep Center of Georgia|
|Principal Investigator:||David Mayleben, PhD||Community Research|
|Principal Investigator:||Neil Feldman, MD||Clinical Research Group of St. Petersburg|
|Principal Investigator:||Russell Rosenberg, PhD||Neurotrials|